【drug-news】皮肤癌药物出现曙光
丁香园临床病例数据库
证书编号：
ldguan
您的案例《【drug-news】皮肤癌药物出现曙光》 经同行评议，被丁香园临床病例数据库收录。
收录时间 2025年3月26日
长按识别二维码
查看病例
查看病例
发布于 2007-09-27 · 浏览 1486 · IP 天津天津
这个帖子发布于 17 年零 185 天前，其中的信息可能已发生改变或有所发展。
http://ap.google.com/article/ALeqM5jXFlVOePfM3uZZiZ1Zx-Ybb43TLQ
Skin Cancer Drug Said to Show Promise
By MARIA CHENG – 1 hour ago
BARCELONA, Spain (AP) — A very early test of an experimental drug seemed to slow the spread of advanced deadly skin cancer in a small study, the drug's U.S. developer reported in preliminary findings Wednesday.
Synta Pharmaceuticals Corp. of Lexington, Mass., reported that patients with advanced melanoma who got the drug survived an average of 3.7 months without new cancer lesions, compared to 1.8 months for those who got the standard treatment.
The treatment, given as a pill, is so early in development it doesn't have a name. It must pass muster in much more rigorous testing before the company seeks U.S. approval.
Synta's drug is one of several in development by other companies trying a new strategy against cancer — killing tumor cells by overloading them with oxygen.
"We are taking advantage of the Achilles heel of cancer cells," said Dr. Anthony Williams, vice president of clinical research at Synta Pharmaceuticals.
The drug has no effect on normal cells, which can adjust to higher levels of oxygen that cause cancer cells to self-destruct.
Doctors who heard the results at the European Cancer Organization meeting were heartened but said further study is needed.
"This could have a profound effect on patients," said Dr. Alex Eggermont, president-elect of the European Cancer Organization and a surgical oncology professor at Erasmus University in Rotterdam, Netherlands. Eggermont was not connected with the study.
The study followed 81 patients with advanced melanoma for about two years. Twenty-eight received the standard chemotherapy drug paclitaxel and lived an average of 1.8 months with no new lesions, while 53 got paclitaxel plus the new drug and survived an average of 3.7 months with no new lesions.
Less than 5 percent of patients taking the new pill suffered serious side effects, such as a temporary drop in white blood cells, back pain and fatigue.
There are very few drugs available for people with advanced melanoma, which kills 70 percent of patients within one year. Globally, about 160,000 people have it.
The company plans a bigger study with more than 600 patients at 150 cancer centers worldwide.
Skin Cancer Drug Said to Show Promise
By MARIA CHENG – 1 hour ago
BARCELONA, Spain (AP) — A very early test of an experimental drug seemed to slow the spread of advanced deadly skin cancer in a small study, the drug's U.S. developer reported in preliminary findings Wednesday.
Synta Pharmaceuticals Corp. of Lexington, Mass., reported that patients with advanced melanoma who got the drug survived an average of 3.7 months without new cancer lesions, compared to 1.8 months for those who got the standard treatment.
The treatment, given as a pill, is so early in development it doesn't have a name. It must pass muster in much more rigorous testing before the company seeks U.S. approval.
Synta's drug is one of several in development by other companies trying a new strategy against cancer — killing tumor cells by overloading them with oxygen.
"We are taking advantage of the Achilles heel of cancer cells," said Dr. Anthony Williams, vice president of clinical research at Synta Pharmaceuticals.
The drug has no effect on normal cells, which can adjust to higher levels of oxygen that cause cancer cells to self-destruct.
Doctors who heard the results at the European Cancer Organization meeting were heartened but said further study is needed.
"This could have a profound effect on patients," said Dr. Alex Eggermont, president-elect of the European Cancer Organization and a surgical oncology professor at Erasmus University in Rotterdam, Netherlands. Eggermont was not connected with the study.
The study followed 81 patients with advanced melanoma for about two years. Twenty-eight received the standard chemotherapy drug paclitaxel and lived an average of 1.8 months with no new lesions, while 53 got paclitaxel plus the new drug and survived an average of 3.7 months with no new lesions.
Less than 5 percent of patients taking the new pill suffered serious side effects, such as a temporary drop in white blood cells, back pain and fatigue.
There are very few drugs available for people with advanced melanoma, which kills 70 percent of patients within one year. Globally, about 160,000 people have it.
The company plans a bigger study with more than 600 patients at 150 cancer centers worldwide.
最后编辑于 2022-10-09 · 浏览 1486
